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Neurophyisological and Neurocognitive Endophenotypes 




There is growing interest in the genetic analysis of schizophrenia using endophenotypes 
rather than clinical diagnosis or symptom dimensions. Endophenotypes could be alternative 
phenotypes for the clinical phenotypes. With their intermedicate and quantitative charac-
teristics, endophenotypes could be functionally important links in the pathways between 
the genetic variation and clinical expression of the disorder. In this regard, the neurophy-
siological and neurocognitive endophenotypes used in the genetic analysis of schizophrenia 
have been reviewed. 
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Concept for Endophenotype 
 
Genetics is all about the relationship between the underlying genotype and mani-
fested phenotypes. The hunt for disease-related genes has proven to be more difficult
than was initially anticipated and has been successful mostly in disorders that are clearly
defined and homogenous. Psychotic disorders have posed a particularly difficult pro-
blem, due to the lack of preciseness in defining the boundaries of the clinical pheno-
type and the absence of objective, biological tests that confirm the diagnostic categori-
zation. In complex diseases such as schizophrenia, there might be a long and winding
pathway between the candidate genes and the clinical diagnosis. In schizophrenia, a 
large amount of genetic studies have been done to elucidate the susceptibility genes
that underlie the phenotype. Until now, there have been no widely accepted suscepti-
bility genes that are related to schizophrenia, even though there is well established evi-
dence that schizophrenia has substantial genetic components. 
This is where the concept of the endophenotype comes in. This concept was first
introduced into the schizophrenia literature by Gottesman and Shields in 1972 and 
was designed to signify quantitative measures that were “intermediate”, functionally im-
portant links in the pathways between genetic variation and the clinical expression of
the disorder.
1 Other terms have been used interchangeably, such as the intermediate 
phenotype, biological marker, subclinical trait, and vulnerability marker. These terms
may not necessarily reflect genetic underpinnings, but rather associated findings. 
Other fields of medicine have had some success in using endophenotypes for ge-
netic studies. For example, the multiple genes causing long QT syndrome were iden-
tified by using QT elongation, as measured by electrocardiogram (ECG), rather than
by using the phenotypes of syncope, ventricle arrhythmias, and sudden death.
2,3 
One strategy to dissect the complex nature of schizophrenia is the analysis of the
quantitative neurobiological deficits, endophenotypes, that are present in schizophrenia
patients and their first-degree biological relatives.
4 As relatively simple, quantifiable 
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fewer genes than the more complex phenotype of schiz-
ophrenia. Endophenotypes were originally defined as mea-
surable components unseen by the unaided eye along the 
pathway between the disease and distal genotype.
4 
An endophenotype-based approach has the potential 
advantage of facilitating the genetic dissection of schiz-
ophrenia, because they would ideally have monogenic 
roots. In reality, however, an endophenotype is a rather 
ill-defined construct that probably involves neurophysio-
logical, biochemical, endocrinological, neuroanatomical, 
cognitive and even neuropsychological factors.
5 Hence, 
the use of endophenotypes needs to be tempered by the 
appreciation that without controls and limits, their use-
fulness may be obscured. A putative endophenotype does 
not necessarily reflect genetic effects. Indeed, these bio-
logical markers may be environmental, epigenetic, or mul-
tifactorial in origin. However, it psychiatric diagnoses 
could be decomposed or deconstructed, I could render 
the genetic analysis more straightforward. 
 
Criteria for Endophenotypes 
 
A number of criteria for evaluating the validity of can-
didate endophenotypes have been suggested.
4,6-9 Among 
them, the following criteria have been the most frequ-
ently adopted. 
1. The endophenotype should be heritable. 
2. The endophenotype should be state-independent. 
3. The endophenotype should be associated with illness 
in the population. 
4. Within families, endophenotype and illness should 
co-segregate. 
The final criterion for an endophenotypic marker has 
two distinct components. First, the marker must co-seg-
regate with the illness within a family. The second com-
ponent specifically relates to diseases with complex in-
heritance patterns. In this case, unaffected family mem-
bers should show some level of disruption on the marker 
compared with the population at large.
10 
In psychiatric fields, a number of attempts have been 
made to develop and determine the feasibility of candi-
date endophenotypes. However, few have met all the 





The ideal neuropsysiological endophenotype is one 
that exhibits a robust and stable deficit in both patients 
and unaffected family members and shows strong evi-
dence of both heritability and co-segregation with ill-
ness within pedigrees. It should also be easily and rap-
idly measured with minimal demands on the subject, 
demonstrate excellent test-retest and across-site reliabi-
lity and, preferably, reflect a discrete neurobiological me-
chanism that is both informative for the pathophysiology 
of the disorder and regulated by a limited number of 
genes.
11 
Inhibitory deficits in schizophrenia have been recog-
nized since long ago.
12 Patients with schizophrenia are 
unable to screen out trivial stimuli and focus on salient 
aspects of the environment. Patients with schizophrenia 
exhibit deficits in several neurophysiological measures 
of information processing that have been proposed as can-
didate endophenotypes. Measures of inhibitory failure in-
clude prepulse inhibition of the startle reflex, P50 audi-
tory evoked potential suppression, and antisaccade eye 
movements. For example, the neurophysiological measures 
in Consortium on the Genetics of Schizophrenia (COGS) 
include P50 auditory evoked potential suppression, pre-
pulse inhibition (PPI) of the startle reflex, and antisac-
cade (AS) eye movements. Measures of impaired deviance 
detection include mismatch negativity and the P300 event-
related potential.   
The p50 suppression test uses two auditory stimuli pre-
sented at 500-msec intervals. The P50 wave is a midlat-
ency auditory evoked potential that exhibits reduced am-
plitude, or suppression, when a second click sound is pre-
sented 500 ms after the initial click. Freedman et al. iden-
tified p50 suppression as an important endophenotype 
of schizophrenia.
13 The use of p50 suppression as a can-
didate endophenotype for genetic studies is further sup-
ported by the identification of significant linkage of p50 
suppression with a genetic marker in the promoter region 
of the alpha-7 subunit of the nicotinic receptor.
14 
PPI is the normal reduction in startle that occurs when 
a starting stimulus is preceded 30-300 ms by a weak 
prestimulus.
15 Prepulse inhibition is a generally conserv-
ed finding among vertebrates and, as such, it has been 
the target of several rodent studies.
4 It is also deficient 
in patients with schizophrenia and their relatives.
16,17 
Abnormal prepulse inhibitions were found in obsessive 
compulsive disorder
18 and Huntington’s disease,
19 among 
others. Elements of the cortico-striato-pallido-thalamic 
circuitry in humans and animal models are known to be 
implicated in the neural regulation of PPI.
20 
The saccadic performance in schizophrenia patients is 
characterized by an increased proportion of antisaccade 
errors.
21 In their more proximal connection to neuronal 
mechanisms, neurophysiological endophenotypes are a 
much stronger signal for the putative disease-related ge-
nes, compared to more variable and complex clinical phe-
notypes.
22 
Neurophysiological measures used in the genetic study 









Cognitive impairments have been considered core fea-
tures of schizophrenia since the time of Bleuler. Cogni-
tive measures along with neurophysiological measures 
are highlighted as endophenotypes for schizophrenia 
recently. There is substantial evidence that measures of 
sustained attention or vigilance, verbal declarative mem-
ory and working memory are valid endophenotypes in 
schizophrenia.  
The Continuous Performance Test (CPT), as neurocog-
nitive measure, is used in the COGS for the measure-
ments of both verbal memory and working memory.
23 
Actually, CPTs are most widely used measures of def-
icits in sustained attention. Among them, the Degraded 
Stimulus Continuous Performance Test (DS-CPT) and 
Continuous Performance Test, Identical Pairs version 
(CPT-IP) are most sensitive tools. These 2 measures 
have shown potential stability over time. CPT impair-
ments are present in schizophrenia even in a clinically 
remitted state. CPTs with high perceptual discrimination 
loads or working memory loads also have been used 
successfully for the detection of neurocognitive deficits 
among biological relatives of patients.   
Deficits in verbal declarative memory (VDM) are one 
of the most prominent cognitive impairments in schizo-
phrenia. The Wechsler Memory Scale, 3
rd edition (WMS-
III), test of story recall (Logical memory, LM)
24 and 
the California Verbal Learning Test, 2
nd edition (CVLT-
II), are the most widely used neurocognitive tests.
25 
Working memory (WM) deficits have been described 
as core cognitive features of schizophrenia.
26 They have 
also been related to the clinically important features of 
schizophrenia, such as poor social and vocational func-
tion.
27,28 Diverse paradigms and specific tests have been 
used to access the construct of working memory. Although 
the heritability estimates of working memory tests do not 
show robust results,
29 working memory deficits seem to 
reflect state independent features that are not due to po-
tential compounds. The Letter-Number Sequencing task 
(LNS)
24 has been selected by the COGS. The LNS and 
related verbal span tasks have been successfully imple-
mented in large, multicenter studies of schizophrenia pa-
tients.
30 
Neurocogntive construct and measures most frequently 
used in the genetic study of schizophrenia are summarized 




The endophenotype strategy could be a powerful and 
effective means of identifying vulnerability genes in 
schizophrenia. There is, however, little convincing evi-
dence yet that the genetic architecture of the endopheno-
types is substantially simpler than that of the schizophre-
nia itself. Many of the endophenotypes remain complex, 
thereby decreasing their utility in a genetic study. Fur-
ther studies need to be done before endophenotypic meas-
ures can be used in the genetic analysis of schizophrenia. 
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